A YouGov snap poll today shows that 71% of English people support this delay, with 41% saying they "strongly” support it.

Young Britons disagree and would rather see coronavirus vaccines being used to protect adults in low income countries

New polling from YouGov shows a majority of British adults say they would support a ban on online ads (57%) or TV ads (58%) promoting junk food.

Many Britons say they would more likely to attend large events if they had requirements for COVID-19 passports

Flexitarians, who follow vegetarianism with the occasional inclusion of meat, form 13% of the UK’s population and 12% in the US.

A new YouGov/Imperial College London webinar explored the first year of the COVID-19 crisis.

Many Britons are yet to make up their minds, but few see it as unsafe

News of the Indian variant does not appear to have made people in England less comfortable returning to public places

ICL and YouGov data explores attitudes towards vaccination.

The public also expect to keep using hand sanitiser frequently and avoiding other people when ill

Britons say the government’s coronavirus guidance is clear, but have different opinions on whether hugging and travelling to a green list destination is encouraged

YouGov and Imperial's COVID tracker dives into how behaviours changed during the pandemic.

The rise in case numbers tied to the new variant has reportedly worried the Prime Minister

A YouGov Direct poll highlights the largest barriers to seeking mental health treatment.

In addition to the costs of transportation, lodging and activities, British consumers will now have to account for how COVID-19 testing factors into their travel budgets.

Around two in five people admit that they have already started socialising indoors

Pfizer and Moderna vaccines seen as safe across all nations studied

For those that are thinking of leaving, pay tops the list of contributing factors

Almost two thirds (64%) of consumers cited lack of exercise or physical activity as a contributing factor towards their weight gain during the pandemic.

AstraZeneca's European woes bleed over into its US BrandIndex performance.